1. Home
  2. DRD vs AUPH Comparison

DRD vs AUPH Comparison

Compare DRD & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DRDGOLD Limited

DRD

DRDGOLD Limited

HOLD

Current Price

$24.02

Market Cap

2.1B

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$16.88

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRD
AUPH
Founded
1895
1993
Country
South Africa
Canada
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
2002
2014

Fundamental Metrics

Financial Performance
Metric
DRD
AUPH
Price
$24.02
$16.88
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $17.86
AVG Volume (30 Days)
197.2K
★ 730.1K
Earning Date
10-23-2026
11-03-2026
Dividend Yield
★ 4.19%
N/A
EPS Growth
N/A
★ 5075.00
EPS
N/A
★ 0.53
Revenue
N/A
★ $283,055,000.00
Revenue This Year
$3.33
$15.83
Revenue Next Year
$18.47
$21.30
P/E Ratio
★ $15.32
$32.60
Revenue Growth
N/A
★ 20.38
52 Week Low
$19.47
$11.89
52 Week High
$39.37
$19.25

Technical Indicators

Market Signals
Indicator
DRD
AUPH
Relative Strength Index (RSI) 42.91 56.75
Support Level $23.19 $15.27
Resistance Level $26.30 $17.16
Average True Range (ATR) 0.65 0.48
MACD 0.07 0.08
Stochastic Oscillator 27.89 73.20

Price Performance

Historical Comparison
DRD
AUPH

About DRD DRDGOLD Limited

DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment, including exploration, extraction, processing, and smelting. Its reportable operating segments are: Ergo and FWGR. Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and FWGR is a surface gold retreatment operation that treats old slime dams in the West Rand goldfields. The Ergo segment derives the vast majority of the company's revenue.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: